Component
Absolute oral arginine bioavailability
Study-scoped entity; inspect species, exposure and experimental limitations on each claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Estimated oral bioavailability was 68 ± 9% after 6 g in eight healthy men.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Oral 6 g, intravenous 6/30 g and placebo comparisons.
- limitations
- Study-specific estimate; another study using 10 g reported approximately 20%. Different dose and analysis prevent treating either as a universal constant.
- nutrient_topic
- L-Arginine collection; tissue, species, dose and formulation distinctions retained. · L-Arginine
- plain_language
- The administered dose and the amount reaching circulation differ.
- primary_references
- L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. · 1998 · https://pubmed.ncbi.nlm.nih.gov/9833603/ · DOI 10.1046/j.1365-2125.1998.00803.x
L-Arginine: transport, metabolic branches, nutrient interactions, availability and discovery questions (2026-09-18) · lines 342–348
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Oral 6 g, intravenous 6/30 g and placebo comparisons. · source_derived_draft · unverified_draft
## arg-pk-six The administered dose and the amount reaching circulation differ. Estimated oral bioavailability was 68 ± 9% after 6 g in eight healthy men. Model: Oral 6 g, intravenous 6/30 g and placebo comparisons. Limitations: Study-specific estimate; another study using 10 g reported approximately 20%. Different dose and analysis prevent treating either as a universal constant. Evidence access: Primary abstract L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. · 1998 · https://pubmed.ncbi.nlm.nih.gov/9833603/ · DOI 10.1046/j.1365-2125.1998.00803.x
Complete structured claim and evidenceA 10 g oral dose had approximately 20% absolute bioavailability in the crossover study.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Ten healthy volunteers; dietary baseline-variation control and 30 g intravenous comparison.
- limitations
- Dose, endogenous baseline and modeling differ from the 6 g study. No mechanism resolving the difference is established here.
- nutrient_topic
- L-Arginine collection; tissue, species, dose and formulation distinctions retained. · L-Arginine
- plain_language
- A second protocol produced a different exposure estimate.
- primary_references
- Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. · 1999 · https://pubmed.ncbi.nlm.nih.gov/10215749/ · DOI 10.1046/j.1365-2125.1999.00883.x
L-Arginine: transport, metabolic branches, nutrient interactions, availability and discovery questions (2026-09-18) · lines 350–356
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Ten healthy volunteers; dietary baseline-variation control and 30 g intravenous comparison. · source_derived_draft · unverified_draft
## arg-pk-ten A second protocol produced a different exposure estimate. A 10 g oral dose had approximately 20% absolute bioavailability in the crossover study. Model: Ten healthy volunteers; dietary baseline-variation control and 30 g intravenous comparison. Limitations: Dose, endogenous baseline and modeling differ from the 6 g study. No mechanism resolving the difference is established here. Evidence access: Primary abstract Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. · 1999 · https://pubmed.ncbi.nlm.nih.gov/10215749/ · DOI 10.1046/j.1365-2125.1999.00883.x
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.